{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:37:59Z","timestamp":1791567479356,"version":"4.3.4"},"reference-count":64,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JNS"],"published-print":{"date-parts":[[2012,10]]},"abstract":"\nObject<\/jats:title>\nAngiogenesis and the platelet-derived growth factor (PDGF) pathway are active in the pathogenesis of vestibular schwannomas (VSs). The purpose of this study was to test whether imatinib mesylate (Gleevec), a PDGF receptor (PDGFR) blocker, reduces angiogenic capacity in sporadic VS and in VS associated with neurofibromatosis Type 2 (NF2) using a corneal angiogenesis assay.<\/jats:p><\/jats:sec>\n\nMethods<\/jats:title>\nFrom 121 VS tissue samples stored in the tumor bank at the Marmara University Institute of Neurological Sciences, 10 samples (6 from sporadic cases, 4 from NF2-associated cases) were selected at random for use in this study. Expression of PDGF-A and PDGF-B and their receptors was evaluated in sporadic and NF2-associated VS as well as in glioblastoma (GBM) and normal brain tissue by means of immunohistochemistry and Western blot analysis. Corneal angiogenesis assay was then used to evaluate the angiogenic capacity of tissue specimens from sporadic and NF2-associated VS with and without imatinib treatment as well as positive and negative controls (GBM and normal brain tissue).<\/jats:p><\/jats:sec>\n\nResults<\/jats:title>\nThe angiogenic potential of the sporadic and NF2-associated VS tumor tissue differed significantly from that of the positive and negative control tissues (p <0.05). Furthermore, NF2-associated VS showed significantly lower angiogenic potential than sporadic VS (p <0.05). Imatinib treatment significantly reduced the angiogenic potential in both the sporadic VS and the NF2-associated VS groups. The level of PDGF-A and PDGFR-\u03b1 as well as PDGF-B and PDGFR-\u03b2 expression in sporadic VS and NF2-associated VS also differed significantly (p <0.05) from the levels in controls. Additionally the level of PDGFR-\u03b2 was significantly higher in sporadic VS than in NF2-associated VS (p <0.05).<\/jats:p><\/jats:sec>\n\nConclusions<\/jats:title>\nThe findings of this study indicate that NF2-associated VS has significantly more angiogenic potential than sporadic VS and normal brain tissue. Additionally, imatinib reduces the angiogenic activity of both sporadic and NF2-associated VS. The authors conclude that imatinib may be a potential treatment for VS, especially for NF2-associated lesions that cannot be cured with resection or radiosurgery.<\/jats:p><\/jats:sec>","DOI":"10.3171\/2012.6.jns112263","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T13:26:48Z","timestamp":1345210008000},"page":"697-704","source":"Crossref","is-referenced-by-count":15,"title":["Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay"],"prefix":"10.3171","volume":"117","author":[{"given":"Ula\u015f","family":"Yener","sequence":"first","affiliation":[{"name":"Institute of Neurological Sciences and"},{"name":"Department of Neurosurgery, Faculty of Medicine, Marmara University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timucin","family":"Avsar","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences and"},{"name":"Dr Orhan \u00d6calgiray Molecular Biology-Biotechnology and Genetics Research Centre, Istanbul Technical University, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Akg\u00fcn","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A\u015fk\u0131n","family":"\u015eeker","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences and"},{"name":"Department of Neurosurgery, Faculty of Medicine, Marmara University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u015far","family":"Bayri","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences and"},{"name":"Department of Neurosurgery, Faculty of Medicine, Marmara University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fcrker","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Institute of Neurological Sciences and"},{"name":"Department of Neurosurgery, Faculty of Medicine, Marmara University; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-jns112263","series-title":"Otol Neurotol","first-page":"163","article-title":"Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma","volume":"32","author":"Altuna","year":"2011"},{"key":"b2-jns112263","series-title":"Neuro Oncol","first-page":"834","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010"},{"key":"b3-jns112263","series-title":"Recent Results Cancer Res","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-540-78281-0_5","article-title":"Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy","volume":"180","author":"Appelmann","year":"2010"},{"key":"b4-jns112263","series-title":"Gan To Kagaku Ryoho","first-page":"1427","article-title":"[Neurofibromatosis type 2 (NF2).]","volume":"24","author":"Araki","year":"1997"},{"key":"b5-jns112263","series-title":"Neurosurgical Operative Atlas: Neuro-Oncology","author":"Badie","year":"2006"},{"key":"b6-jns112263","series-title":"Food Chem Toxicol","first-page":"1334","article-title":"Tumor angiogenesis\u2014a potential target in cancer chemoprevention","volume":"46","author":"Bhat","year":"2008"},{"key":"b7-jns112263","series-title":"Int J Oncol","first-page":"255","article-title":"The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer","volume":"34","author":"Bran","year":"2009"},{"key":"b8-jns112263","series-title":"Acta Otolaryngol","first-page":"1040","article-title":"Expression of angiogenic growth factors in acoustic neurinoma","volume":"123","author":"Brieger","year":"2003"},{"issue":"Suppl 5","key":"b9-jns112263","series-title":"Eur J Cancer","first-page":"S28","article-title":"Pharmacology of imatinib (STI571)","volume":"38","author":"Buchdunger","year":"2002"},{"key":"b10-jns112263","series-title":"Cancer Res","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996"},{"key":"b11-jns112263","series-title":"J Neurooncol","first-page":"181","article-title":"Skull base surgery for benign skull base tumors","volume":"69","author":"Bulsara","year":"2004"},{"key":"b12-jns112263","series-title":"J Neurosci","first-page":"1642","article-title":"Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration","volume":"17","author":"Carroll","year":"1997"},{"key":"b13-jns112263","series-title":"Laryngoscope","first-page":"2129","article-title":"Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate","volume":"113","author":"Cay\u00e9-Thomasen","year":"2003"},{"key":"b14-jns112263","series-title":"Otol Neurotol","first-page":"98","article-title":"VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate","volume":"26","author":"Cay\u00e9-Thomasen","year":"2005"},{"key":"b15-jns112263","series-title":"Otol Neurotol","first-page":"846","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study","volume":"29","author":"Clark","year":"2008"},{"key":"b16-jns112263","series-title":"Otol Neurotol","first-page":"559","article-title":"Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression","volume":"28","author":"Diensthuber","year":"2007"},{"key":"b17-jns112263","series-title":"Otol Neurotol","first-page":"50","article-title":"ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy","volume":"29","author":"Doherty","year":"2008"},{"key":"b18-jns112263","series-title":"Nat Med","first-page":"561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996"},{"key":"b19-jns112263","series-title":"Curr Treat Options Oncol","first-page":"115","article-title":"Imatinib mesylate and its potential implications for gynecologic cancers","volume":"6","author":"Dushkin","year":"2005"},{"key":"b20-jns112263","series-title":"J Neurosurg","first-page":"906","article-title":"The molecular biology and novel treatments of vestibular schwannomas. A review","volume":"115","author":"Fong","year":"2011"},{"key":"b21-jns112263","series-title":"J Neurosurg","first-page":"440","article-title":"Analysis of risk factors associated with radiosurgery for vestibular schwannoma","volume":"95","author":"Foote","year":"2001"},{"key":"b22-jns112263","series-title":"J Natl Cancer Inst","first-page":"413","article-title":"Tumor growth and neovascularization: an experimental model using the rabbit cornea","volume":"52","author":"Gimbrone","year":"1974"},{"key":"b23-jns112263","series-title":"Rev Neurol (Paris)","first-page":"765","article-title":"[Neurofibromatosis type 2.]","volume":"163","author":"Goutagny","year":"2007"},{"key":"b24-jns112263","series-title":"J Neurosurg","first-page":"917","article-title":"Efficacy of facial nerve-sparing approach in patients with vestibular schwannomas. Clinical article","volume":"115","author":"Haque","year":"2011"},{"key":"b25-jns112263","series-title":"Ear, Nose, and Throat Disorders Sourcebook","author":"Judd","year":"2007"},{"key":"b26-jns112263","series-title":"Auris Nasus Larynx","first-page":"15","article-title":"Clinical picture of vestibular schwannoma","volume":"28","author":"Kentala","year":"2001"},{"key":"b27-jns112263","series-title":"Cancer Res","first-page":"5143","article-title":"Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class","volume":"60","author":"Kilic","year":"2000"},{"key":"b28-jns112263","series-title":"Nature","first-page":"841","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993"},{"key":"b29-jns112263","series-title":"Neurosurgery","first-page":"1339","article-title":"Testing the angiogenic potential of cerebrovascular malformations by use of a rat cornea model: usefulness and novel assessment of changes over time","volume":"56","author":"Konya","year":"2005"},{"key":"b30-jns112263","series-title":"Otol Neurotol","first-page":"1094","article-title":"Expression of vascular endothelial growth factor and basic fibroblast growth factor in sporadic vestibular schwannomas correlates to growth characteristics","volume":"28","author":"Koutsimpelas","year":"2007"},{"key":"b31-jns112263","series-title":"Cancer Chemother Pharmacol","first-page":"779","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008"},{"issue":"Suppl","key":"b32-jns112263","series-title":"J Neurosurg","first-page":"195","article-title":"Radiosurgery of vestibular schwannomas: summary of experience in 829 cases","volume":"102","author":"Lunsford","year":"2005"},{"key":"b33-jns112263","series-title":"Clin Cancer Res","first-page":"681","article-title":"Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation","volume":"10","author":"Matei","year":"2004"},{"key":"b34-jns112263","series-title":"Textbook of Tinnitus","first-page":"317","article-title":"Tinnitus and vestibular schwannoma: overview and clinical correlations","author":"May","year":"2010"},{"key":"b35-jns112263","series-title":"J Neurosci Res","first-page":"491","article-title":"Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggests modulation of ERM proteins by merlin","volume":"62","author":"Meng","year":"2000"},{"key":"b36-jns112263","series-title":"Laryngoscope","first-page":"657","article-title":"Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1","volume":"120","author":"M\u00f8ller","year":"2010"},{"key":"b37-jns112263","series-title":"Cancer Res","first-page":"5099","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate)","volume":"69","author":"Mukherjee","year":"2009"},{"key":"b38-jns112263","series-title":"Mol Endocrinol","first-page":"225","article-title":"Elevated expression of basic fibroblast growth factor messenger ribonucleic acid in acoustic neuromas","volume":"3","author":"Murphy","year":"1989"},{"key":"b39-jns112263","series-title":"Adv Cancer Res","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(01)80010-5","article-title":"Involvement of platelet-derived growth factor in disease: development of specific antagonists","volume":"80","author":"Ostman","year":"2001"},{"key":"b40-jns112263","series-title":"Adv Cancer Res","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","article-title":"PDGF receptors as targets in tumor treatment","volume":"97","author":"Ostman","year":"2007"},{"key":"b41-jns112263","series-title":"Cancer Cell","first-page":"439","article-title":"PDGF receptors as cancer drug targets","volume":"3","author":"Pietras","year":"2003"},{"key":"b42-jns112263","series-title":"N Engl J Med","first-page":"358","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009"},{"key":"b43-jns112263","series-title":"Neurosurgery","first-page":"241","article-title":"Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience","volume":"58","author":"Pollock","year":"2006"},{"key":"b44-jns112263","series-title":"Neurosurgery","first-page":"77","article-title":"Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery","volume":"59","author":"Pollock","year":"2006"},{"key":"b45-jns112263","series-title":"Neurosurgery","first-page":"475","article-title":"Vestibular schwannoma management in the next century: a radiosurgical perspective","volume":"43","author":"Pollock","year":"1998"},{"key":"b46-jns112263","series-title":"J Neurosurg","first-page":"527","article-title":"Improved preservation of hearing and facial nerve function in vestibular schwannoma surgery via the retrosigmoid approach in a series of 200 patients","volume":"105","author":"Samii","year":"2006"},{"key":"b47-jns112263","series-title":"Prog Neurol Surg","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000156905","article-title":"Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results","volume":"21","author":"Samii","year":"2008"},{"key":"b48-jns112263","series-title":"J Neurosurg","first-page":"860","article-title":"Functional outcome after complete surgical removal of giant vestibular schwannomas. Clinical article","volume":"112","author":"Samii","year":"2010"},{"key":"b49-jns112263","series-title":"Neurosurgery","first-page":"11","article-title":"Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them","volume":"40","author":"Samii","year":"1997"},{"key":"b50-jns112263","series-title":"Neurosurgery","first-page":"159","article-title":"Expression of integrins in cerebral arteriovenous and cavernous malformations","volume":"58","author":"Seker","year":"2006"},{"key":"b51-jns112263","series-title":"Neurosurgery","first-page":"1335","article-title":"True incidence of vestibular schwannoma?","volume":"67","author":"Stangerup","year":"2010"},{"key":"b52-jns112263","series-title":"Laryngoscope","first-page":"457","article-title":"Epidermal growth factor receptor expression by acoustic neuromas","volume":"106","author":"Sturgis","year":"1996"},{"key":"b53-jns112263","series-title":"Neurosurgery","first-page":"744","article-title":"Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence","volume":"66","author":"Sun","year":"2010"},{"key":"b54-jns112263","series-title":"Neurosurgery","first-page":"1724","article-title":"Relationship of angiogenic potential with clinical features in cranial meningiomas: a corneal angiogenesis study","volume":"67","author":"Toktas","year":"2010"},{"key":"b55-jns112263","series-title":"Laryngoscope","first-page":"736","article-title":"Incidence of vestibular schwannomas","volume":"109","author":"Tos","year":"1999"},{"key":"b56-jns112263","series-title":"Oncogene","first-page":"5054","article-title":"STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications","volume":"20","author":"Tuveson","year":"2001"},{"key":"b57-jns112263","series-title":"J Neurooncol","first-page":"259","article-title":"Expression of VEGF and its receptor genes in intracranial schwannomas","volume":"83","author":"Uesaka","year":"2007"},{"key":"b58-jns112263","series-title":"J Neurosurg","first-page":"875","article-title":"Management of large vestibular schwannoma. Part I. Planned subtotal resection followed by Gamma Knife surgery: radiological and clinical aspects. Clinical article","volume":"115","author":"van de Langenberg","year":"2011"},{"key":"b59-jns112263","series-title":"J Neurosurg","first-page":"885","article-title":"Management of large vestibular schwannoma. Part II. Primary Gamma Knife surgery: radiological and clinical aspects. Clinical article","volume":"115","author":"van de Langenberg","year":"2011"},{"key":"b60-jns112263","series-title":"Cancer Res","first-page":"1464","article-title":"Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase","volume":"59","author":"Wang","year":"1999"},{"key":"b61-jns112263","series-title":"Oncogene","first-page":"3521","article-title":"Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571","volume":"19","author":"Wang","year":"2000"},{"key":"b62-jns112263","series-title":"Curr Opin Otolaryngol Head Neck Surg","first-page":"341","article-title":"Molecular studies of vestibular schwannomas: a review","volume":"15","author":"Welling","year":"2007"},{"key":"b63-jns112263","series-title":"J Clin Oncol","first-page":"124","article-title":"Taming glioblastoma by targeting angiogenesis: 3 years later","volume":"29","author":"Wong","year":"2011"},{"key":"b64-jns112263","series-title":"J Clin Oncol","first-page":"4705","article-title":"Taming glioblastoma: targeting angiogenesis","volume":"25","author":"Wong","year":"2007"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/117\/4\/article-p697.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/117\/4\/article-p697.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/117\/4\/article-p697.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:38:02Z","timestamp":1679873882000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/117\/4\/article-p697.xml"}},"subtitle":["Laboratory investigation"],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":64,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3171\/2012.6.jns112263","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}